Cutting-Edge Expertise for Insightful Research
At Galileo Research, we transform scientific potential into tangible solutions, offering end-to-end non-clinical research and development services.

Comprehensive Non-Clinical Services

Galileo Research offers an extensive range of non-clinical research and development services that validate the safety, efficacy, and unique claims of products across diverse industries. With deep expertise in pharmaceuticals, medical devices, novel foods, dietary supplements, and botanicals, we help companies – startups, SMEs, and global enterprises – deliver safe and effective innovations to the market with hyper-tailored research protocols. Spanning from in silico, in vitro, or in vivo studies, we support and optimize the product’s R&D journey, overcoming and managing regulatory barriers. Our services cover:

Project Management and Regulatory Expertise

With a dedicated Project Management Team, Galileo ensures seamless execution of non-clinical testing programs to cover all aspects of development. From planning to regulatory submissions for Clinical Trial Applications (CTAs), Investigational New Drugs (INDs), and other regulatory filings under EMA, FDA, and other global authorities, we provide expert strategic guidance to ensure compliance with international standards*, including ICH, OECD, EFSA and ISO frameworks.

Our meticulous approach guarantees close to 100% regulatory submission compliance, while also enabling high-tech players in fast-developing markets to adapt effectively to new regulatory requirements, ensuring their innovation aligns with evolving global requirements.

Flagship Domains:

Advanced Therapies

Galileo Research supports innovation in the field of advanced therapies and biotechnological products due to the pioneering experience in oncology cell therapy, now in the clinical development phase.

Key Therapeutic Areas:

Digital Tools

Our state-of-the-art digital platform, including in silico and bioinformatic tools, streamlines data management and analysis of a vast amount of data generated during non-clinical studies. These technologies enable faster, more precise evaluations, reducing time-to-market while enhancing decision-making.